A supplier provided "incorrect ingredients" for the items sold across the United States, Mexico and Ecuador, the FDA said.

Generated LUMRYZ™ net revenue of $68.1 million, a 64% increase compared to second quarter 2024, net income of $9.7 million and earnings per share of $0.10 ---- 3,100 patients on LUMRYZ as of June 30, ...